SCHEMBL155348

SCHEMBL155348

[O]C12CCC(CC1)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL155496 0.89
SCHEMBL2288424 0.87
SCHEMBL151703 0.87
SCHEMBL154813 0.81
SCHEMBL155312 0.79
SCHEMBL25418462 0.73
SCHEMBL1440930 0.69
SCHEMBL155699 0.69
SCHEMBL155741 0.65 GRIN2D (0.44)
SCHEMBL2112375 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10745372-B2 Compound, resin, material for forming underlayer film for lithography, underlayer film for lithography, pattern forming method, and purification method MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2020-08-18 US claimed
US-6245774-B1 ANTIINFLAMMATORY AGENTS; BRONCHODILATOR AGENTS CELLTECH THERAPEUTICS LIMITED (GB) 2001-06-12 US claimed
US-4477464-A Hetero-benzazepine derivatives and their pharmaceutical use CIBA-GEIGY CORPORATION (US) 1984-10-16 US claimed
US-12018024-B2 Compounds and compositions for the treatment of cryptosporidiosis NOVARTIS AG (CH) 2024-06-25 US disclosed
WO-2024102849-A1 BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY NIKANG THERAPEUTICS, INC. (US) 2024-05-16 WO disclosed
US-11937495-B2 Organic light emitting element, composition and membrane KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2024-03-19 US disclosed
US-20240009189-A1 1,4-DISUBSTITUTED PYRIDAZINE QUINOLNE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONS NOVARTIS AG (CH) 2024-01-11 US disclosed
EP-3843168-B1 ORGANIC LIGHT EMITTING ELEMENT, COMPOSITION AND MEMBRANE UNIV KYUSHU NAT UNIV CORP (JP) 2023-10-11 EP disclosed
US-20230295373-A1 THERMOPLASTIC RESIN COMPOSITION FOR OPTICAL MATERIAL, MOLDED ARTICLE, COMPOUNDING AGENT, METHOD FOR PRODUCING THERMOPLASTIC RESIN COMPOSITION, AND METHOD FOR IMPROVING TRANSMISSIVITY MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2023-09-21 US disclosed
EP-4229055-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CRYPTOSPORIDIOSIS Novartis AG (CH) 2023-08-23 EP disclosed
EP-4227304-A2 THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS Novartis AG (CH) 2023-08-16 EP disclosed
US-20020034654-A1 Organic electroluminescent device having high luminance efficiency NEC CORPORATION 2002-03-21 US disclosed
EP-0667857-A1 INDOLYLCARBAMATES AS ANTI-INFLAMMATORY AGENTS PFIZER INC. (US) 1995-08-23 EP disclosed
WO-1994010144-A1 INDOLYLCARBAMATES AS ANTI-INFLAMMATORY AGENTS PFIZER INC. (US) 1994-05-11 WO disclosed
US-5280039-A Bicyclic carbamates and methods of treating inflammatory diseases using the same PFIZER INC. (US) 1994-01-18 US disclosed
EP-0405391-A1 Certain (arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids and derivatives thereof CIBA-GEIGY AG (CH) 1991-01-02 EP disclosed
EP-0163433-B1 ANTIBACTERIAL SOLID COMPOSITION FOR ORAL ADMINISTATION Takeda Chemical Industries, Ltd. (JP) 1990-08-01 EP disclosed
EP-0354180-A2 Certain imidazo[4,5-b]pyridine derivatives CIBA-GEIGY AG (CH) 1990-02-07 EP disclosed
US-4616008-A LIPID-SOLUBLE CEPHALOSPORINS AND CYCLODEXTRINS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1986-10-07 US disclosed
US-4477464-A Hetero-benzazepine derivatives and their pharmaceutical use CIBA-GEIGY CORPORATION (US) 1984-10-16 US disclosed